A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2170
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
BIOLOGICAL:
risankizumab
Sponsor
AbbVie